Swine Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Swine Vaccines Market is Segmented by Product (Inactivated Vaccines, Attenuated Live Vaccines, Recombinant Vaccines, and Others), Disease Type (Classical Swine Fever (CSF), Porcine Parvovirus, Swine Influenza, and More), Route of Administration (Injectables, Intranasal, and Oral), and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Swine Vaccines Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Swine Vaccines Market with other markets in Healthcare Industry

Swine Vaccines Market Analysis by Mordor Intelligence

The swine vaccines market is valued at USD 1.81 billion in 2025 and is forecast to reach USD 2.32 billion by 2030, advancing at a 5.09% CAGR. Strong growth reflects a permanent shift from treating outbreaks to preventing them, as biosecurity rules tighten and producers protect herds that are more valuable than ever. Vaccination already offsets the USD 1.2 billion lost each year to porcine reproductive and respiratory syndrome, turning immunization from an optional cost into standard risk control. Technology disruption reinforces expansion: RNA particle platforms cut custom vaccine lead times to 12–16 weeks, while gene-edited pigs resistant to PRRS broaden the toolbox beyond traditional antigens. Regionally, North America holds 38.45% 2024 revenue on the back of advanced veterinary infrastructure, whereas Asia-Pacific posts the fastest CAGR at 6.23% as producers rebuild after African swine fever. Inactivated products stay ahead with 46.77% share, but recombinant lines grow at 6.02% as buyers favor safer DIVA-compliant options.

Key Report Takeaways

  • By product type, inactivated formulations led with 46.77% of the swine vaccines market share in 2024; recombinant platforms are set to expand at a 6.02% CAGR through 2030.  
  • By disease type, classical swine fever accounted for 40.22% of the swine vaccines market size in 2024, while swine influenza is projected to climb at a 5.98% CAGR to 2030.  
  • By route of administration, injectable vaccines held 76.34% of 2024 revenue; intranasal delivery is forecast to grow at a 6.12% CAGR over 2025–2030.  
  • By geography, North America captured 38.45% revenue in 2024; Asia-Pacific is the fastest-growing region at 6.23% CAGR through 2030.

Segment Analysis

By Product: Recombinant Platforms Drive Innovation

In 2024, inactivated vaccines claimed 46.77% of the swine vaccines market share thanks to decades of field success and straightforward production. Recombinant lines post the fastest 6.02% CAGR to 2030 as buyers prize DIVA features that keep trade channels open. Attenuated live options remain in use for robust cellular immunity, though safety rules curtail volumes in high-density farms. Recombinant tools also ease updates when viral genotypes drift beyond current strain panels. The swine vaccines market size for recombinant products is positioned to accelerate as regulators gain experience with platform approvals.

The mRNA wave underscores this tilt toward precision. Sequivity’s RNA particles, ready in 12–16 weeks, contrast sharply with classical antigen culture timelines. PEDV spike-mRNA prototypes already trigger stronger responses than inactivated benchmarks. Meanwhile, oral and nanobody-based ideas broaden the “Others” bucket by tackling ease-of-use and stronger mucosal immunity. Together these shifts indicate that future sales will track how quickly each supplier can update antigens while keeping pricing inside producer budgets.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Disease Type: Classical Swine Fever Dominance Faces Influenza Challenge

Classical swine fever vaccines contributed 40.22% of 2024 revenue as the disease carries heavy trade and mortality penalties. Live-attenuated FlagT4G shows how efficacy can coexist with DIVA tags, supporting eradication drives and verification testing. Swine influenza formulations grow at 5.98% CAGR because zoonotic risks and rapid viral drift push regular updates. Studies in China link vaccination pressure to faster H1N1 evolution, proving that constant surveillance and reformulation are essential.

Porcine parvovirus products deliver steady returns by safeguarding litter sizes, while circovirus vaccines shift to bivalent blends covering PCV2 and PCV3 variants. Research groups fast-track ASF candidates now that farm trials can replicate natural infection. The swine vaccines industry expects more disease-specific platforms that tailor immunity without compromising diagnostics.

By Route of Administration: Injectable Dominance Meets Intranasal Innovation

Injectable delivery accounted for 76.34% of 2024 sales, reflecting veterinarian familiarity and precise dosing. Intradermal products such as PORCILIS PCV M Hyo ID reduce needle volume and stress but keep the core injection model. The swine vaccines market size for intranasal routes is rising on a 6.12% trajectory as producers seek lower labor and stronger mucosal defense. Influenza-vectored intranasal trials show protection at the pathogen’s entry point.

Oral sprays and feed-based carriers serve niche mass-piglet programs, yet stability challenges limit their spread. Needle-free jet devices trim injury risk and enhance throughput. As AI monitoring becomes common, farms can match precise respiratory scores with intranasal boosters, raising the likelihood that alternative routes will chip away at injectable dominance.

Swine Vaccines Market: Market Share by Route of Administration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America generated 38.45% of 2024 revenue, supported by strict biosecurity and well-funded producers willing to pay for autogenous and RNA solutions. Federal plans such as the Swine Health Improvement Plan formalize traceability and vaccination compliance. Canada’s USD 57.5 million vaccine bank for foot-and-mouth disease signals public investment in rapid response. The swine vaccines market size in North America is also buoyed by a deep cold-chain and dense veterinary service network that ensures uptake.

Asia-Pacific registers the fastest 6.23% CAGR as the region rebuilds inventories after ASF. China’s restocking proves that coordinated vaccination, enhanced genetics, and modern barns stabilize supply. The Philippines runs supervised ASF vaccination using a Vietnamese-developed candidate, testing efficacy under field stress. Vietnam’s smart-farming push prices vaccination between USD 4.7 and 9 per pig and demonstrates willingness to pay when productivity gains are clear. Thailand’s rising pork appetite compounds momentum.

Europe, the Middle East and Africa, and South America offer varied prospects. Europe’s FMD cases in 2024 forced emergency vaccine orders that protected export licenses. The bloc’s rigorous approval process slows new entrants yet builds end-user confidence, supporting steady demand for premium recombinant products. Middle East and African markets struggle with cold-chain gaps, inviting thermostable formulations. South America’s export players adopt DIVA vaccines to secure market access, expanding volume while raising bar for compliance among domestic peers.

Swine Vaccines Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The swine vaccines market shows moderate concentration. Zoetis, Merck Animal Health, and Boehringer Ingelheim anchor the top tier with broad portfolios and global distribution. Zoetis markets more than 300 animal-health products and maintains deep technical support, which shields share even as niche rivals appear. Merck leverages Sequivity to target precision needs and is scaling output through a USD 895 million Kansas build-out. Boehringer’s Dynamic Pig Health program integrates ten FLEX vaccines with gut-health brands to cover respiratory and enteric threats in one protocol.

Mid-tier firms broaden capabilities through acquisitions. Phibro spent USD 350 million on Zoetis’ medicated feed additive assets, pairing nutrition and vaccine lines to create bundled health solutions. Technology specialists focus on narrow breakthroughs: mRNA start-ups iterate immunogens in weeks, adjuvant innovators supply nanobody boosters, and software firms turn sensor data into vaccination-timing alerts. Larger incumbents respond by forming research pacts or buying these niche skills outright.

Competition now hinges on five levers: platform speed, strain-update agility, cold-chain simplicity, combined respiratory-enteric coverage, and digital integration. Firms that align all five command pricing power, while laggards face commoditization in basic inactivated products. The swine vaccines market continues to reward scale economies along with differentiated science.

Swine Vaccines Industry Leaders

  1. Merck & Co., Inc.

  2. Elanco

  3. Boehringer Ingelheim International GmbH

  4. Zoetis Inc.

  5. Ceva Sante Animale

  6. *Disclaimer: Major Players sorted in no particular order
Swine Vaccines Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2025: EMA issued a positive opinion for Biobhyo to prevent swine dysentery caused by Brachyspira hyodysenteriae.
  • May 2025: The Pirbright Institute and The Vaccine Group began African swine fever vaccine challenge trials using a virulent field strain.
  • February 2025: Virbac introduced a neonatal piglet diarrhea vaccine in Europe.
  • March 2024: Merck Animal Health secured USDA approval for Sequivity paired with Microsol Diluvac Forte to extend immunity in custom RNA particle vaccines.

Table of Contents for Swine Vaccines Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Government Initiatives Toward Swine-Flu Management & Higher Public Awareness
    • 4.2.2 Growth In R&D Outlays for Novel Vaccine Platforms
    • 4.2.3 Escalating Global Pork Consumption & Intensifying Bio-Security Mandates
    • 4.2.4 Rapid-Response Autogenous/RNA Platforms Shorten Time-To-Immunity
    • 4.2.5 AI-Driven Herd Analytics Enable Precision Vaccination & Lower TCO
    • 4.2.6 Trade-Oriented Shift Toward DIVA-Compliant Vaccines
  • 4.3 Market Restraints
    • 4.3.1 High Cold-Chain Costs & Risk of Adverse Reactions
    • 4.3.2 Lengthy, Stringent Regulatory Approval Cycles
    • 4.3.3 Viral Genotype Drift Outpacing Vaccine Strain Updates
    • 4.3.4 Budget Diversion To Antibiotic-Free Certification Programs
  • 4.4 Regulatory Landscape
  • 4.5 Porters Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product
    • 5.1.1 Inactivated Vaccines
    • 5.1.2 Attenuated Live Vaccines
    • 5.1.3 Recombinant Vaccines
    • 5.1.4 Others
  • 5.2 By Disease Type
    • 5.2.1 Classical Swine Fever (CSF)
    • 5.2.2 Porcine Parvovirus
    • 5.2.3 Swine Influenza
    • 5.2.4 Porcine Circovirus (PCV)
    • 5.2.5 Others
  • 5.3 By Route of Administration
    • 5.3.1 Injectables
    • 5.3.2 Intranasal
    • 5.3.3 Oral
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Merck Animal Health (MSD)
    • 6.3.2 Zoetis Inc.
    • 6.3.3 Boehringer Ingelheim
    • 6.3.4 Ceva Sante Animale
    • 6.3.5 Elanco Animal Health
    • 6.3.6 HIPRA
    • 6.3.7 Phibro Animal Health
    • 6.3.8 Virbac
    • 6.3.9 Vaxxinova
    • 6.3.10 Biogenesis Bago
    • 6.3.11 KM Biologics
    • 6.3.12 Indian Immunologicals
    • 6.3.13 Huvepharma
    • 6.3.14 IDT Biologika
    • 6.3.15 Newport Labs (Boehringer)
    • 6.3.16 Epitopix
    • 6.3.17 Ouro Fino Saude Animal
    • 6.3.18 Jinyu Bio-technology
    • 6.3.19 CAHIC (China Animal Husbandry)
    • 6.3.20 Ringpu (Ringpu Biotech)

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Swine Vaccines Market Report Scope

As per the scope of the report, swine vaccines are generally given to pigs and contain antigens from bacteria, viruses, parasites, or bacterial toxins. It helps to promote an immune response in pigs, which protects against natural infection from which the vaccine has been derived. The swine vaccines market is segmented by product (inactivated vaccines, attenuated live vaccines, recombinant vaccines, and others), disease type (classical swine fever, porcine parvovirus, swine influenza, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD) for the above segments.

By Product Inactivated Vaccines
Attenuated Live Vaccines
Recombinant Vaccines
Others
By Disease Type Classical Swine Fever (CSF)
Porcine Parvovirus
Swine Influenza
Porcine Circovirus (PCV)
Others
By Route of Administration Injectables
Intranasal
Oral
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product
Inactivated Vaccines
Attenuated Live Vaccines
Recombinant Vaccines
Others
By Disease Type
Classical Swine Fever (CSF)
Porcine Parvovirus
Swine Influenza
Porcine Circovirus (PCV)
Others
By Route of Administration
Injectables
Intranasal
Oral
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the swine vaccines market?

The market stands at USD 1.81 billion in 2025 and is projected to grow steadily to USD 2.32 billion by 2030.

Which region leads swine vaccine revenue today?

North America holds 38.45% of global revenue owing to advanced veterinary infrastructure and strict biosecurity rules.

Which product segment is growing the fastest?

Recombinant vaccines record the highest 6.02% CAGR through 2030 as producers adopt safer, DIVA-ready platforms.

Why are intranasal vaccines gaining attention?

They stimulate local respiratory immunity, cut labor time, and are forecast to expand at 6.12% CAGR over 2025–2030.

What are the main restraints affecting market growth?

High cold-chain costs in developing regions and lengthy regulatory approvals together shave roughly 1.6 percentage points off potential CAGR.

How are rapid-response RNA platforms changing the landscape?

Technologies such as Sequivity cut vaccine customization cycles to 12–16 weeks, enabling quicker containment of new viral strains.

Page last updated on: July 1, 2025

Swine Vaccines Market Report Snapshots